Vitamin A Compound Or Derivative Patents (Class 514/725)
  • Patent number: 10265363
    Abstract: The present invention provides formulations that support an individual's body during routine vaccination and adaptive immune response. The individuals who can benefit front these formulations are infants, children and adults. The formulations comprise ingredients that can be administered prior to, concurrent with or subsequent to the vaccination. The formulations of the present invention preferably act by targeting enzymatic reactions an individual's various metabolic pathways, maintaining balance between oxidative stress and methylation, maintaining balance between Th1 and Th2 responses, or a combination thereof during vaccination and adaptive immune response.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: April 23, 2019
    Inventors: Sarah Morgan, Karl Holtzer
  • Patent number: 10201510
    Abstract: Particular aspects of the present invention provide pharmaceutical compositions comprising isoprenoid-based compounds (e.g., farnesol and/or farnesol analogs or derivatives) or dehydroisoprenoid-based compounds, and novel methods for using same in treating (e.g., suppressing): alcohol withdrawal syndrome and associated neurological symptoms (e.g., depression, tremor, anxiety, autonomic hyperactivity (e.g., sweating, increased blood pressure, tachycardia), hallucinations, alcohol withdrawal seizures, delirium tremens (DT), and memory loss); or for treating in treating convulsive seizure (e.g., epileptic seizure, etc.).
    Type: Grant
    Filed: February 6, 2006
    Date of Patent: February 12, 2019
    Assignee: Oregon Health & Science University
    Inventors: Jean-Baptiste Roullet, John C. Crabbe, Jr., Pamela Metten
  • Patent number: 9889173
    Abstract: The present invention provides a composition for improving macular pigment optical density and preventing or treating age-related macular optical degeneration. The composition comprises lutein, zeaxanthin and tea extracts, wherein the weight ratio of zeaxanthin to lutein is more than or equal to 1. The composition may prevent formation of choroidal neovascularization to achieve effects on comprehensively preventing or treating age-related macular optical degeneration (AMD).
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: February 13, 2018
    Assignee: Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory
    Inventors: Xinde Xu, Lihua Zhang, Xiaoxia Sun
  • Patent number: 9872908
    Abstract: The present disclosure provides for a composition which may be used for the solublization of an agent or the oral administration of an agent, the composition comprising, a lyosphosphatidyl compound and at least one of a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises a lyosphosphatidyl compound, a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises an agent, a lyosphosphatidyl compound, a monoglyceride and a free fatty acid.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: January 23, 2018
    Assignee: Avanti Polar Lipids, Inc.
    Inventors: Walter A Shaw, Stephen W Burgess, Shengrong Li
  • Patent number: 9833489
    Abstract: Use of saffron and its active ingredients, such as safranal and/or picrocrocin and/or crocin and/or derivatives thereof, for the production of an active satiation agent for the treatment of problems of overweight.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: December 5, 2017
    Inventor: Cedric Bourges
  • Patent number: 9533048
    Abstract: The present invention provides a composition comprising or consisting of components (a) (i) at least one mono-alkanoyl glycerol ester, wherein alkanoyl is selected from C4 to C21 alkanoyl, preferably from octanoyl and decanoyl; and (b) (i) at least one compound selected from cholesterol, phosphatidyl cholines and phosphatidyl glycerols, wherein the acyl moieties of the phosphatidyl moieties are independently selected from C6 to C21 alkanoyl and C6 to C21 alkenoyl.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: January 3, 2017
    Assignee: ARISGEN SA
    Inventors: Paolo Botti, Sylvie Tchertchian
  • Patent number: 9422363
    Abstract: The present invention provides methods for using synthetic apolipoprotein E (ApoE)-mimicking peptides. Also disclosed are methods for using synthetic apolipoprotein E (ApoE)-mimicking peptides to reduce plasma glucose levels. Methods of using the disclosed apolipoprotein E (ApoE)-mimicking peptides to treat diabetes and diabetic complications are also disclosed.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: August 23, 2016
    Assignee: UAB RESEARCH FOUNDATION
    Inventors: Gattadahalli M. Anantharamaiah, C. Roger White, Himanshu Gupta
  • Patent number: 9408786
    Abstract: A composition for the treatment of skin comprises a non-emulsified, aqueous suspension of retinol. The composition may further include at least one protein species, and some proteins used in the composition include collagen and elastin. The composition may also include hyaluronic acid. The composition may also include one or more of tocopheryl acetate, propylene glycol, and linseed extract. Also disclosed are methods for making the composition and use of the composition for the treatment of skin.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: August 9, 2016
    Assignee: Biopelle, Inc.
    Inventor: Elliott Milstein
  • Patent number: 9254277
    Abstract: The present invention provides food compositions that are effective in treating arthritis or inflammation associated with arthritis in a companion animal, preferably a canine or feline.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: February 9, 2016
    Assignee: HILLS'S PET NUTRITION, INC.
    Inventors: Ryan Michael Yamka, Nolan Zebulon Frantz, Samer Al-Murrani
  • Patent number: 9168240
    Abstract: The present invention provides food compositions and methods for companion animals that are effective in preventing or treating obesity.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: October 27, 2015
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Ryan Michael Yamka, Nolan Zebulon Frantz, Samer Al-Murrani
  • Patent number: 9125940
    Abstract: Provided are compositions and methods for the treatment of macular edema, in particular that results from central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), age related macular degeneration (AMD), diabetes, or eye surgical procedures. The composition strengthens retinal health through the prevention, stabilization and/or treatment of macular edema. The composition can include polyphenolic compounds extracted from natural plants, an alpha lipoic acid, docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA), and ubiquinone.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: September 8, 2015
    Inventors: Zhuning Ma, Jingran Chen
  • Patent number: 9116045
    Abstract: A UV exposure dosimetry system includes at least one UV sensor that accurately measures the UV irradiance intensity. The UV dosimetry system integrates the measured UV irradiance intensity over time to calculate the real-time UV dosage and the vitamin D production by taking into account factors comprising UV sensor location, body surface area, clothing coverage, and the effective sun protection factor of the applied sunscreen. Based on the measurement, the system can predict the time remaining to skin burn and the time remaining to reach daily goal of vitamin D production. The UV dosimetry system supports multi-user control through an advanced and user friendly input and output interface.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: August 25, 2015
    Inventors: Jie Lian, Nabyl Bennouri, Nattapon Chaimanonart
  • Patent number: 9029135
    Abstract: The invention relates to a nucleic acid comprising a sequence complementary to a fragment of the sequence coding for the kanamycin resistance protein. This nucleic acid is useful as a DNA vaccine adjuvant, and can be used e.g. for treating cancer, for example in combination with a non-immunosuppressive inducer of tumor cell apoptosis such as all-trans retinoic acid (ATRA).
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: May 12, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (Inserm), Universite Paris Diderot-Paris 7
    Inventors: Rose Ann Padua, Christine Chomienne
  • Patent number: 9029423
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: May 12, 2015
    Assignee: GW Pharma Limited
    Inventor: Brian Anthony Whittle
  • Patent number: 8987244
    Abstract: Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) drug induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the h
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: March 24, 2015
    Assignee: PhilERA New Zealand Limited
    Inventors: Garth J. S. Cooper, John R. Baker
  • Patent number: 8980293
    Abstract: The present invention relates to a method for stabilizing retinol (Vitamin A), an unstable fat-soluble material, to use the same in cosmetics. The present invention provides an anti-inflammatory and skin wrinkle reducing cosmetic composition containing retinol stabilized by nano-emulsification, wherein a retinol polymer nanocapsule formed by capturing retinol with porous polymer particles is nano-emulsified by a mung bean MCT (medium chain triglyceride) extract and lecithin for stabilizing retinol.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: March 17, 2015
    Assignee: Act Co., Ltd.
    Inventors: Sang-Ho Jeong, Ji-Hyun Son, Su-Jin Jang, Yun-Jeong Kim, Jong-Woo Cheon
  • Publication number: 20150051296
    Abstract: A composition and a method that is effective to reduce, limit, or diminish one or more side effects of a retinoid are described. The composition includes a retinoid and a free fatty acid. The composition may further include one or more cosmetically suitable ingredients so long as they do not interfere with the efficaciousness of the free fatty acid. The method for reducing, limiting, or diminishing a side effect associated with the topical administration of a retinoid to a skin area of a subject includes topically administering a free fatty acid to the skin area prior to, during, and/or after topical administration of the retinoid.
    Type: Application
    Filed: August 7, 2014
    Publication date: February 19, 2015
    Applicant: Access Business Group Internaional LLC
    Inventors: John F. Rebhun, Rodney A. Velliquette, Samantha Westveer
  • Publication number: 20150031544
    Abstract: The present invention relates to formulations and methods for stabilizing and protecting of biologic materials during harsh storing and use conditions, wherein the formulations relate to embedded bioactive materials and biologics, including live bacteria, in a protective glassy matrix.
    Type: Application
    Filed: August 11, 2014
    Publication date: January 29, 2015
    Applicant: Advanced Bionutrition Corporation
    Inventors: Moti HAREL, Roger Drewes, January Scarbrough
  • Patent number: 8936800
    Abstract: Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, selected from the group consisting of (a) polyacrylamide gelling agents, (b) gelling agents which are acrylic polymers coupled to hydrophobic chains, (c) modified starch gelling agents, and mixture thereof, said composition maintaining good chemical stability of (i) and (ii) without their degradation over time at a temperature of between 4° C. and 40° C.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: January 20, 2015
    Assignee: Galderma Research & Development
    Inventors: Sandrine Orsoni, Nathalie Willcox
  • Patent number: 8927528
    Abstract: A composition to be administered to a mammal for treating hearing loss is disclosed herein. The composition consists essentially of a biologically effective amount of vitamin A, vitamin C, vitamin E, and a vasodilator comprising magnesium. The composition optionally includes a withanolide and/or resveratrol. The vitamin A, vitamin C, vitamin E, and the vasodilator comprising magnesium provides an additive effect that is equal to or greater than a sum of the effects of the individual components.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: January 6, 2015
    Assignee: The Regents of the University of Michigan
    Inventors: Josef Miller, Colleen LePrell, Jochen Schact, Diane Prieskorn
  • Publication number: 20150004238
    Abstract: Stable vitamin oil-in-water emulsions and methods of making those emulsions are described herein. The emulsions may be used to make beverage products that include fat-soluble vitamins. The emulsions may also be used in beverage products that are colored and which maintain color stability for an extended period of time.
    Type: Application
    Filed: August 5, 2014
    Publication date: January 1, 2015
    Inventors: Archana N.M.I. Khangaonkar, Jeffrey D. Nutt
  • Patent number: 8921423
    Abstract: Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: December 30, 2014
    Assignee: Galderma Research & Development
    Inventors: Michael Graeber, Janusz Czernielewski
  • Publication number: 20140370110
    Abstract: The invention encompasses micelle assemblies, compositions having micelle assemblies, and methods for preparing micelle assemblies and compositions thereof. The invention also encompasses a prolamine protein conjugated to a polymer, such as a polyethylene glycol (PEG) chain, which conjugates can be used to prepare micelle assemblies. The invention further encompasses methods of encapsulating molecules using the conjugates of the invention. The micelle assemblies can be used for a variety of applications, such as treating cancer, targeting tumors, reducing the toxicity of a drug in vivo, increasing the efficacy of an encapsulated agent in vivo, protecting an encapsulated agent against degradation, and enhancing the water solubility of a drug or other agent.
    Type: Application
    Filed: April 8, 2014
    Publication date: December 18, 2014
    Applicant: SOUTH DAKOTA STATE UNIVERSITY
    Inventors: Omathanu P. Perumal, Satheesh K. Podaralla, Ranjith Kumar Averineni
  • Publication number: 20140357709
    Abstract: (Modified) sorghum protein is used as novel protective hydrocolloid for active ingredients, especially fat-soluble active ingredients and/or colorants. Included are compositions comprising (modified) sorghum protein and at least one active ingredient and to their manufacture, as well as to the (modified) sorghum protein itself and its manufacture. These compositions are used for the enrichment, fortification and/or coloration of food, beverages, animal feed, personal care or pharmaceutical compositions, and to food, beverages, animal feed, personal care and pharmaceutical compositions containing such a (modified) sorghum protein and such a composition, respectively.
    Type: Application
    Filed: August 13, 2014
    Publication date: December 4, 2014
    Applicant: DSM IP ASSETS B.V.
    Inventor: Christian SCHAEFER
  • Patent number: 8900607
    Abstract: The present invention relates to compositions including anhydrous compositions which include dimethicone crosspolymer and/or dimethicone elastomer gum and one or more skin care products which may include retinoic acid, retinoic acid derivatives, retinal, retinol and/or retinyl esters.
    Type: Grant
    Filed: May 26, 2004
    Date of Patent: December 2, 2014
    Assignee: Chemsil Silicones, Inc.
    Inventors: James Jeffries Harrison, Nohemi Harrison
  • Patent number: 8895628
    Abstract: A composition including a retinoid, an NF?B-inhibitor, and a cosmetically-acceptable topical carrier is provided. Methods of treating the skin are also provided.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: November 25, 2014
    Assignee: Johnson & Johnson Consumer Companies, Inc.
    Inventor: Thierry Oddos
  • Patent number: 8889194
    Abstract: Disclosed is a compound and methods for use by an individual attempting to reduce or cease tobacco smoking or one exposed to environmental tobacco smoke. The compound includes a first component blocking nicotine receptor sites to reduce nicotine cravings or withdrawal symptoms, a second component increasing serotonin levels and acting synergistically with the first component to reduce nicotine cravings or withdrawal symptoms, assisting in maintaining body weight and reducing increased stress and anxiety, and a third component acting synergistically with the first and/or second component to reduce nicotine cravings or withdrawal symptoms, maintain body weight, and/or reduce increased stress and anxiety. The third component comprises a supplement that replenishes depleted body substance(s), repairs damaged body substance(s), and/or ameliorates the impaired function of body substance(s). Some combination of the first, second, and third component alters the perceived taste of tobacco smoke.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: November 18, 2014
    Inventor: Harlan Clayton Bieley
  • Patent number: 8877820
    Abstract: A composition including a retinoid, an NF?B-inhibitor, and a cosmetically-acceptable topical carrier is provided. Methods of treating the skin are also provided.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: November 4, 2014
    Assignee: Johnson & Johnson Consumer Companies, Inc.
    Inventor: Thierry Oddos
  • Publication number: 20140322340
    Abstract: The present invention provides protein (or peptide)-polysaccharide (or oligosaccharide) conjugates (PPC) as nanocapsular vehicles for nanoencapsulation of biologically active compounds, particularly nutraceuticals. The PPCs efficiently protect both hydrophobic (i.e., water insoluble) and hydrophilic (i.e., water soluble) nutraceuticals, to provide a composition which, when added to a beverage, disperses so as to provide a clear or transparent solution. In some embodiments, the PPCs are Maillard reaction based PPCs. Advantageously, the conjugates of the present invention protect the nutraceuticals from degradation, both during shelf life and upon gastric digestion.
    Type: Application
    Filed: May 4, 2014
    Publication date: October 30, 2014
    Applicant: Technion Research and Development Foundation LTD.
    Inventor: Yoav D. Livney
  • Patent number: 8865233
    Abstract: Compositions containing about 0.6% to about 20% of tea tree oil are described. Some compositions are in the form of solutions, suspensions, spray, lotions, gels, pastes, medicated sticks, balms, cleansers (including shampoos and soaps), creams, or ointments. Also described are compositions and methods for use in treating ocular Demodex infestations and related conditions using such compositions.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: October 21, 2014
    Assignee: Tissuetech, Inc.
    Inventors: Ying-Ying Gao, Scheffer Tseng
  • Publication number: 20140308353
    Abstract: A composition for use as a topical delivery system for an active material is provided, the composition comprising a plurality of skin cell removal particles and a plurality of active material molecules, at least some of the skin cell removal particles each carrying at least one active material molecule, wherein carrying of an active material molecule by a skin cell removal particle maintains activity of the active material molecule. A topical delivery system for an active material, and a method of topical delivery of an active material are also provided.
    Type: Application
    Filed: July 27, 2012
    Publication date: October 16, 2014
    Inventors: Roghieh Saffie-Siebert, Nasrollah Torabi-Pour
  • Publication number: 20140302169
    Abstract: A method wherein subjects having or at risk for having hyperopia, presbyopia or astigmatism are administered a composition having an effective amount of ocular antioxidants, including specifically macular pigments, to prevent, treat, or delay the onset of age-related macular degeneration (AMD).
    Type: Application
    Filed: June 18, 2014
    Publication date: October 9, 2014
    Inventor: Richard Roberts
  • Patent number: 8852615
    Abstract: The present invention relates to compositions including anhydrous compositions which include a dimethicone crosspolymer and/or dimethicone elastomer gum and one or more skin care products which may include retinoic acid, retinoic acid derivatives, retinal, retinol and/or retinyl esters, and methods of making, storing, and using such compositions.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: October 7, 2014
    Assignee: Chemsil Silicones, Inc.
    Inventors: James Jeffries Harrison, Nohemi Harrison
  • Publication number: 20140294787
    Abstract: Nutritional products having improved cohesiveness of food boluses and methods of making and using same are provided. The nutritional products may include nutritional compositions and high molecular weight, water-soluble polymers such that the nutritional products have extensional viscosities that provide improved cohesiveness to the nutritional products and Trouton ratios of at least 6. Methods of administering such nutritional products to patients having impaired swallowing ability and/or dysphagia are also provided.
    Type: Application
    Filed: March 1, 2012
    Publication date: October 2, 2014
    Inventors: Adam Stewart Burbidge, Jan Engmann, Simina Popa Nita
  • Publication number: 20140271596
    Abstract: The present invention relates to an emulsified hydrogel composition and to a production method therefor, wherein, by incorporating between 20 and 30 percent by weight of a gelling solution and an emulsion obtained by mixing between 45 and 60 percent by weight of an aqueous component and between 15 and 30 percent by weight of an oil component, it is possible to simultaneously provide the skin with an aqueous fraction and an oil fraction, and it is possible to enhance functionality due to the inclusion of a high content of a dermatologically active component dissolved in the oil component.
    Type: Application
    Filed: September 12, 2012
    Publication date: September 18, 2014
    Applicant: GENIC CO., LTD.
    Inventors: Sung Jang Kim, Hyong-ii Park, Jae Han Cho, Eun Kyoung Choi, Jae hoon Kwak, Jae Min Lim, Hyun Jun Lim, Jai Hyun Kim, Min Seok Kim, Jin A. Yang, Hyun Oh Yoo, Jong Chul Kim
  • Patent number: 8821904
    Abstract: A topical composition and its use for the prophylaxis and the treatment of defects connected to inflammatory dermopathies. Particularly, a topical composition including at least an alum, 18-?-glycyrrhetic acid and/or one derivative thereof, and vitamin A and/or one derivative thereof, and the use of such composition for the prophylaxis and the treatment of inflammatory dermopathies, preferably of the seborrhoeic dermatitis and of those affections in which the presence of an excess of sebum occurs.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: September 2, 2014
    Assignee: Skinius S.R.L.
    Inventor: Antonino Di Pietro
  • Publication number: 20140242153
    Abstract: Disclosed are novel methods for making cochleates and cochleate compositions that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compositions that include an aggregation inhibitor, and optionally, a cargo moiety. Additionally, anhydrous cochleates that include a protonized cargo moiety, a divalent metal cation and a negatively charge lipid are disclosed. Methods of using the cochleate compositions of the invention, including methods of administration, are also disclosed.
    Type: Application
    Filed: January 30, 2014
    Publication date: August 28, 2014
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Raphael J. Mannino, Susan Gould-Fogerite, Sara L. Krause-Elsmore, David Delmarre, Ruying Lu
  • Publication number: 20140242179
    Abstract: The present patent application relates to a novel coating system, coated compositions with such a coating system, as well as to the use of such compositions in the production food, feed, dietary supplements and/or pharmaceutical products, as well as to food, feed, dietary supplements and/or pharmaceutical products comprising such compositions.
    Type: Application
    Filed: October 11, 2012
    Publication date: August 28, 2014
    Applicant: DSM IP ASSETS B.V.
    Inventors: Sylvain Diguet, Bruno H. Leuenberger, Fabien Laboulfie, Mehrdji Hemati
  • Patent number: 8815955
    Abstract: A method wherein subjects having or at risk for having hyperopia, presbyopia or astigmatism are administered a composition having an effective amount of ocular antioxidants, including specifically macular pigments, to prevent, treat, or delay the onset of age-related macular degeneration (AMD).
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: August 26, 2014
    Assignee: Kemin Industries, Inc.
    Inventor: Richard Roberts
  • Patent number: 8815954
    Abstract: The invention is directed to a strategy for providing therapeutic or cosmetic benefit to skin by topically applying arginine chemically bound to a second (non-oligoarginine) compound in order to increase transepithelial delivery of arginine through a combination of increased solubility and flux across the skin. The arginine heteromers of the invention can add other complementary or beneficial properties for the skin beyond those that are arginine-related.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: August 26, 2014
    Assignee: Revance Therapeutics, Inc.
    Inventor: Jacob M. Waugh
  • Patent number: 8815936
    Abstract: Described is a composition for preventing or treating an oxidative stress related disease or condition in a subject. The disease or condition is characterized by the presence of excess oxidative compounds in the subject, and the composition includes a synergistic combination of therapeutically effective amounts of resveratrol to promote NAD+ synthesis in the subject; a chelating agent to reduce production of additional oxidative compounds in the subject; and an antioxidant to minimize the oxidative activity in the subject.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: August 26, 2014
    Assignee: Nad Life Pty Ltd
    Inventors: Ross Stewart Grant, Nady Braidy, Gilles Guillemin, George Smythe
  • Publication number: 20140228429
    Abstract: The present invention relates to a process for the production of extruded formulations comprising oil-in-water emulsion droplets, to such formulations as well as to the use.
    Type: Application
    Filed: May 20, 2012
    Publication date: August 14, 2014
    Applicant: DSM IP ASSETS B.V
    Inventors: Elger Funda, Alexandra Teleki, Leonardus Gerardus Bernardus Bremer, Pierre Elemans, Adriaan Willem Meesen
  • Patent number: 8802732
    Abstract: A carotenoid and a terpenoid in therapeutically-effective amounts is disclosed such that, upon ingestion in one preparation, or in two separated preparations, simultaneous or sequentially, and upon metabolism, the activity of natural killer (NK) cells is elevated. Specifically, the composition comprises lycopene and resveratrol in the range of 1:10 to 10:1 by molar; more preferably 1:1 to 3:1 by molar, and most preferably at 3:1. Alternatively, the preferred ratio may be expressed as 1:4 to 25:1 by weight; more preferably 2½:1 to 7½:1 by weight, and most preferably at 7½:1. The composition may be formulated for oral intake as a pharmaceutical, dietary supplement or food product and provided in therapeutically effective amounts to a mammal, preferably in a dosage of about 3.5 mg per day per 20 g of a mammalian body mass in a ratio of 2½:1 by weight, which can be translated to about 400 mg to 1000 mg per day for a typical human in need of elevating NK cell activity.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: August 12, 2014
    Assignee: Hsiehs Biotech (Singapore) Pte Ltd
    Inventor: Kun Lung Hsieh
  • Publication number: 20140220109
    Abstract: A process for producing a small-sized, lipid-based cochleates. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca2+ or Zn2+, forms a cochleate precipitate of a particle size less than one micron. The process may be used to produce cochleates containing biologically relevant molecules.
    Type: Application
    Filed: December 31, 2013
    Publication date: August 7, 2014
    Applicant: Rutgers, The State University of New Jersey
    Inventors: Leila Zarif, Tuo Jin, Ignacio Segarra, Raphael J. Mannino
  • Publication number: 20140212474
    Abstract: Compositions that can include a carrier, targeting agent, and therapeutic agent are disclosed herein. The therapeutic agent may have a therapeutic activity such as inhibiting fibrosis within a target organ or tissue or inhibiting the growth of a cancer cell.
    Type: Application
    Filed: January 29, 2014
    Publication date: July 31, 2014
    Applicant: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Lei Yu, Gang Zhao, Sang Van, Fu Chen
  • Patent number: 8771760
    Abstract: The present invention relates to treatment of cancer related pain and constipation. Preferably the subject in need is administered a combination of the cannabinoids cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: July 8, 2014
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Philip Robson
  • Publication number: 20140186302
    Abstract: The present invention provides methods for treating retinal disorders using a nutraceutical composition comprising lutein and zeaxanthin. Methods for treating vitreomacular traction disorder and related disorders are disclosed.
    Type: Application
    Filed: December 28, 2012
    Publication date: July 3, 2014
    Inventor: Barbara L. DUNNING
  • Publication number: 20140161855
    Abstract: A cosmetic including two different systems for procurement of actives in the human skin and enhancing the collagen I synthesis. The cosmetic with enhanced collagen I synthesis can include 0.001 to 2% by weight, related to the total weight of the cosmetic, of a first retinol-containing system including retinol encapsulated in a chitosan and carboxymethyl cellulose shell, 0.001 to 3.5% by weight, related to the total weight of the cosmetic, of a second retinol-containing system including cationic liposomes composed of phospholipids and with a quaternary fatty acid monoamine with C21-C23 alkyl residue and the difference to 100% by weight of cosmetic subsidiaries. Very small amounts of retinol in combination with both transport systems show a remarkable effect on the synthesis of collagen I in comparison with one or more other known combinations of retinol derivatives or encapsulated systems.
    Type: Application
    Filed: July 13, 2012
    Publication date: June 12, 2014
    Applicant: Monsanto Technology LLC a corporation
    Inventors: Olivier Doucet, Muriel Pujos, Cécile Robert, Dorothée Bernini
  • Publication number: 20140155359
    Abstract: A clear and nutritive microemulsion comprising an aqueous phase in which at least one liposoluble active ingredient is dispersed, a first surfactant included in the group consisting of non-ionic surfactants with a high HLB and non-ionic surfactants with medium HLBs; and a second surfactant, characterized in that said second surfactant is chosen from the group consisting of anionic surfactants which have an HLB ?25.
    Type: Application
    Filed: July 13, 2012
    Publication date: June 5, 2014
    Applicant: PRAYON
    Inventors: Guy Broze, Claire Pucci, Adeline Navarro
  • Patent number: 8729127
    Abstract: Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: May 20, 2014
    Assignee: Galderma Research & Development
    Inventors: Michael Graeber, Janusz Czernielewski